Saturday 17 October 2026 Export OMER’s income statement to Excel — free account

Omeros Corporation

In the quarter to June 2026, revenue grew 35.5%, EPS grew 141.9%, free cash flow grew 118.7% and total debt fell 42.0%, each against the same quarter a year earlier.

16.20 2.59 −13.78%

Follow OMER

Alert me

Market cap: $1.4B
P/E: 9.5×
Fwd P/E: 2.1×
Dividend yield: —
F-score: 2/9
Altman Z: −6.82
Beneish M: −0.06
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 3.04

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	1	—	—	—	1	—	—	5	1	—

Insider Ownership 3.94%

Capital & Financial Ratios $m

Market Cap 1,360.00

Revenue 97.25

Net Income 124.83

Free Cash Flow (68.74)

Net Debt (34.70)

Current Ratio 1.95

Debt/Equity (1.89)

P/E ratio 9.47

Fwd P/E 2.06

P/S ratio 12.02

P/B ratio 0.00

Past 5Y EPS Growth —

This Y EPS Growth 1,913.33%

Next Y EPS Growth 16.54%

Next Y revenue growth 268.29%

Next 5Y EPS Growth 35.27%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 66.35%

10-year low 10-year high

EV/Sales against its own 10 years 61.30%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	172	90	172	132
Receivables	8	8	11	21
Inventory	—	—	—	1
Other	29	29	25	26
	218	134	216	185

	2023	2024	2025	Q'26
Payables	8	6	5	6
ST’ Debt	—	21	—	—
Other	9	21	21	22
	53	80	78	95

Compound Annual Growth %

	10y	5y	3y
Sales	42.72%	40.44%	4.42%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	0.00%	0.00%	0.00%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	22	27	30	33	—
’18	2	2	5	22	30
’17	12	17	22	14	65

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(15)	4	—	—	—
’25	(36)	(22)	(18)	(40)	(116)
’24	(42)	(46)	(32)	(29)	(149)
’23	175	(32)	(33)	(35)	75
’22	(15)	(19)	(26)	(25)	(86)
’21	(40)	(28)	(24)	(18)	(110)
’20	(9)	(38)	(35)	(18)	(100)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(15)	4	—	—	—
’25	(36)	(22)	(18)	(40)	(116)
’24	(42)	(46)	(32)	(29)	(149)
’23	175	(33)	(33)	(35)	74
’22	(15)	(20)	(26)	(25)	(87)
’21	(40)	(28)	(24)	(18)	(110)
’20	(9)	(38)	(35)	(18)	(100)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	0.62	0.15	—	—	—
’25	(0.58)	(0.43)	(0.47)	0.98	(0.05)
’24	(0.63)	(0.97)	(0.56)	(0.54)	(2.70)
’23	(0.54)	(0.59)	(0.60)	(0.15)	(1.88)
’22	(0.53)	(0.49)	(0.28)	2.05	0.76
’21	(0.57)	(0.46)	(0.36)	4.48	3.12
’20	(0.53)	(0.61)	(0.66)	(0.60)	(2.41)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	7.20	8.71	8.36	10.88	8.50	5.45	1.74	0.92	2.61	2.95	Analyst estimates 2026–2028 Powerpack
	High	16.80	27.09	27.00	20.92	25.46	23.85	7.75	7.80	13.60	17.65
People
People	Employees	154	173	236	258	277	213	196	198	202	175
	Revenue/emp, $m	0.27	0.37	0.13	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Income, $m
Income, $m	Revenue	42	65	30	—	—	—	—	—	—	—
	Gross margin, %	96.61	98.34	98.29	97.63	(2.19)	0.00	0.00	—	—	—
	EBT	(67)	(53)	(140)	(167)	(196)	(192)	(182)	(175)	(180)	(3)
	EBT margin, %	(160.38)	(82.50)	(467.68)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Net income	(67)	(53)	(127)	(84)	(138)	194	47	(118)	(157)	(3)
	Depreciation	0	1	1	2	2	1	3	3	(3)	(1)
Per share, $
Per share, $	Revenue	1.03	1.42	0.61	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Earnings	(1.65)	(1.17)	(2.61)	(1.71)	(2.41)	3.12	0.76	(1.88)	(2.70)	(0.05)
	Cash flow	(1.27)	(0.80)	(2.14)	(1.21)	(1.75)	(1.76)	(1.38)	1.19	(2.56)	(1.83)
	Capex	0.00	(0.01)	(0.01)	(0.01)	0.00	0.00	0.00	(0.01)	0.00	0.00
	Free cash flow	(1.28)	(0.80)	(2.15)	(1.22)	(1.76)	(1.76)	(1.38)	1.18	(2.56)	(1.83)
	Book value	(0.93)	(0.06)	(2.06)	(2.20)	(2.11)	0.38	1.37	(0.40)	(3.14)	(1.91)
	Shares, m	40	46	49	50	57	62	63	63	58	64
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	—	—	—	—	—
	P/S	9.82	14.16	18.12	6.24	11.07	—	—	—	—	—
	P/B	0.00	0.00	0.00	0.00	0.00	—	—	—	—	—
	EV/Sales	10.64	14.16	21.08	7.14	12.49	—	—	—	—	—
	EV/FCF	(8.57)	(25.09)	(6.04)	(13.22)	(9.19)	—	—	—	—	—
Cash, $m
Cash, $m	Operating cash flow	(52)	(36)	(104)	(60)	(100)	(110)	(86)	75	(149)	(116)
	Capex	0	0	(1)	0	0	0	0	0	0	0
	Free cash flow	(52)	(37)	(104)	(60)	(100)	(110)	(87)	74	(149)	(116)
Balance, $m
Balance, $m	Working capital	44	82	53	48	115	196	307	165	55	138
	Total debt	80	84	150	162	240	319	315	213	188	209
	Net debt	34	0	89	101	105	161	120	41	97	37
	Shareholders’ equity	(37)	(3)	(100)	(109)	(121)	24	86	(25)	(183)	(121)
Returns, %
Returns, %	ROA	(114.81)	(58.26)	(119.43)	(72.55)	(86.83)	64.71	9.39	(24.31)	(47.86)	(1.11)
	ROIC	0.00	0.00	0.00	0.00	0.00	(58.58)	(49.56)	(629.94)	0.00	0.00
	ROE	209.62	265.67	246.20	80.78	120.17	(400.60)	86.63	(388.17)	151.08	2.21

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2018 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
ANAB AnaptysBio, Inc.	$1.5B	— (loss-making)	220×	−7.98% (below 0%: shrinking)	n/m	−141.60% (below 0%: shrinking)	100.00%	(135.53%)	Compare
RAPP Rapport Therapeutics, Inc.	$1.4B	— (loss-making)	—	—	n/m	−64.75% (below 0%: shrinking)	100.00%	0.00%	Compare
AAPG Ascentage Pharma Group International - Unsponsored ADR	$1.4B	—	—	—	—	+17.74% (above 0%: growing)	—	—	Compare
OMER Omeros Corporation	$1.4B	9.5×	2.1×	+35.46% (above 0%: growing)	n/m	+118.70% (above 0%: growing)	97.20%	0.26%
INBX Inhibrx Biosciences, Inc.	$1.3B	— (loss-making)	— (loss-making)	+992.44% (above 0%: growing)	n/m	+0.12% (above 0%: growing)	100.00%	0.00%	Compare
ORIC Oric Pharmaceuticals, Inc.	$1.3B	— (loss-making)	—	—	n/m	−3.42% (below 0%: shrinking)	0.00%	0.00%	Compare
TYRA Tyra Biosciences, Inc.	$1.3B	— (loss-making)	—	—	n/m	−31.34% (below 0%: shrinking)	0.00%	0.00%	Compare
GHRS GH Research PLC	$1.3B	— (loss-making)	—	—	n/m	−66.62% (below 0%: shrinking)	0.00%	0.00%	Compare
NKTR Nektar Therapeutics	$1.3B	— (loss-making)	— (loss-making)	−9.34% (below 0%: shrinking)	n/m	−65.73% (below 0%: shrinking)	100.00%	(417.94%)	Compare
Median of peers	$1.3B	—	—	−7.98%	—	−48.04%	100.00%	0.00%

All 614 Biotechnology stocks →

Omeros Corporation (OMER) key facts

Omeros Corporation (OMER) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, OMER traded at $16.20, a market capitalization of $1.4 billion.
Return on equity was 2.21% and debt-to-equity -1.89.

Source: company filings (standardised) and stockrow calculations.